Navigation Links
Pneumonia Drug Promising Against Form of Muscular Dystrophy
Date:11/12/2009

In studies with mice, pentamidine combats genetic defects that lead to myotonic dystrophy

THURSDAY, Nov. 12 (HealthDay News) -- Researchers report that a drug used to treat pneumonia might serve as an effective treatment against a type of muscular dystrophy.

They tested the drug pentamidine in mice and found that it appears to combat genetic defects that lead to type 1 myotonic dystrophy, one of nine types of muscular dystrophy. The muscle-wasting condition is also known as DM1 and Steinart's disease.

The levels used in mice would be poisonous in humans, but University of Oregon chemist J. Andrew Berglund, whose lab tested the drug, said it could be modified.

Pentamidine is approved to treat several conditions, including a severe type of pneumonia in people with compromised immune systems, some yeast infections and sleeping sickness.

"Pentamidine is an exciting lead compound because it is relatively easy to chemically modify, and hopefully one of these modified compounds could lead to a safe, long-term treatment for DM1 in the future," said Berglund.

The study, funded in part by the U.S. National Institutes of Health and the Muscular Dystrophy Association, was published in the Nov. 3 issue of Proceedings of the National Academy of Sciences.

More information

Learn more about muscular dystrophy from the National Institutes of Health.



--Randy Dotinga



SOURCE: University of Oregon, press release, Nov. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Zinc Helps Elderly Ward Off Pneumonia
2. Heart attacks/pneumonia falls short of national goals
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
5. Pneumonia Vaccine Is Keeping Kids Healthier
6. Treating Childhood Pneumonia at Home Could Save Lives in Developing Countries
7. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
8. Community-Based Staph Pneumonia More Common Than Thought
9. TB Drug Treatment Can Lead to Severe Pneumonia
10. Antipsychotic drugs increase risk of developing pneumonia in elderly
11. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Austin, TX (PRWEB) , ... December 05, 2016 ... ... Center for Facial Plastic Surgery, is excited to announce the arrival of the ... hybrid fractional laser, with the ability to use tunable non-ablative and ablative wavelengths ...
(Date:12/5/2016)... ... , ... Researchers at Johns Hopkins All Children’s Hospital want to learn more ... course of three years, researchers will study concussions and changes in brain function by ... special sensors, will track the location and force of the hit. The sensors store ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
(Date:12/5/2016)... ... ... Sideline Products is a Southern York County Pennsylvania-based premier designer and manufacturer founded ... Smaller saddles can pinch and irritate the horse creating safety issues and limiting comfort ... saddle so it does not impact the comfort or performance of the horse. Further, ...
(Date:12/5/2016)... ... 05, 2016 , ... The legislation – S2718A/A2116A ... a licensed physical therapist, to render care for certain patients. In most cases, ... a licensed physical therapist (PT) and throughout the treatment cycle is supported by ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAS VEGAS , Dec. 5, 2016  BD ... a leading global medical technology company, will demonstrate an ... BD medication management technologies, including the company,s leading Pyxis™ ... of Health-System Pharmacists (ASHP) 2016 Midyear Meeting being ... Dec. 4-8. While national data show that ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... , , The ... billion by 2021, at a CAGR of 5.3% from 2016 to 2021. ... of obesity cases, increasing government spending on healthcare, and rising income levels ...
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
Breaking Medicine Technology: